Highlights from ASCO
June 5, 2023
Dr Claudio Cerchione summarised the educational session on the management of multiple myeloma in special patient populations, such as elderly and patients with renal failure.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the support of:
Daily highlights
Project in the spotlight
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
In-depth stories
Updates from GMMG-HD7
December 19, 2024
In this video, Dr Elias Mai, haematologist at the Heidelberg University Hospital in Germany and one of the lead investigator of GMMG-HD7, shares the key take-aways of these abstracts.
Five-year follow-up of the phase II OPTIC study
December 19, 2024
In this video, Prof Jorge Cortes, haematologist at the Georgia Cancer Centre in Augusta, Georgia (USA), discusses the 5-year follow up data of this trial presented at ASH 2024.
Frontline ponatinib plus blinatumomab for Ph+ ALL
December 18, 2024
In this video, Prof Robin Foà, emeritus professor of haematology at the Sapienza University of Rome discusses two abstracts presented at ASH zooming in on the use of ponatinib plus
Updates from the EAE115 and IONA-MM studies
December 18, 2024
In this video, Prof Fredrik Schjesvold, head of the Oslo myeloma center in Oslo (Norway), discusses the results of the EAE 115 study evaluating this regimen as a second line
MRD negativity dynamics in the IMROZ study
December 16, 2024
Dr Robert Orlowski, a haematologist at the University of Texas MD Anderson Cancer Center in Houston, Texas, provided a comprehensive summary of his presentation on MRD testing in the context
inMIND study in R/R follicular lymphoma
December 13, 2024
Prof Marek Trneny, haematologist at Charles University General Hospital in Prague, Czech Republic, presented findings from the inMIND study, featured as a late-breaking abstract at the ASH meeting.
DREAMM-7 study in R/R MM
December 13, 2024
Prof Dr Claudio Cerchione, a haematologist at the Istituto Romagnolo per lo Studio dei Tumori in Meldola, Italy, co-authored the DREAMM-7 study and shared updated efficacy data presented at ASH
AALL1731 trial
December 12, 2024
Dr Sumit Gupta, a paediatric oncologist and assistant professor at the Hospital for Sick Children and the University of Toronto, Canada, presented the main findings of the AALL1731 study, of
Poster selection
Extracellular vesicles from chronic lymphocytic leukemia cells induce the differentiation of monocytes into nurse-like cells
June 9, 2023
What is the impact of BCR stimulation on miRNA content in CLL cells and EVs? And what is the impact of CLL-EVs on moncytes? That’s what this study aims to
A dual role for PSIP1 in T-ALL
June 9, 2023
This study identifies the role of PSOP1 in the initiation and maintenance of T-ALL, by analyzing the effects caused by PSIP1 loss, both in mice models and human T-ALL cell
Real-world insights on the management of iTTP with Caplacizumab
June 9, 2023
The aim of this project is to determine the effective concentration (EC) of TXA using the GFC/LT, to facilitate TXA use in surgery or trauma. For this, the research team
Effective concentration of TXA using the GFC/LT
June 9, 2023
The aim of this project is to determine the effective concentration (EC) of TXA using the GFC/LT, to facilitate TXA use in surgery or trauma. For this, the research team
A Novel Mammalian L-ASNase in the treatment of T-ALL
June 9, 2023
n this study, a research group from Ghent University aims to develop a less toxic an non immunogenic L-ASNase with similar L-ASNase activity as FDA-approved L-ASNase, but without the toxic